PXS vs. STX, CHLL, VLG, SNG, ABDX, GENI, DEST, NSCI, KNB, and INHC
Should you be buying Provexis stock or one of its competitors? The main competitors of Provexis include Shield Therapeutics (STX), Chill Brands Group (CHLL), Venture Life Group (VLG), Synairgen (SNG), Abingdon Health (ABDX), GENinCode (GENI), Destiny Pharma (DEST), NetScientific (NSCI), Kanabo Group (KNB), and Induction Healthcare Group (INHC). These companies are all part of the "medical" sector.
Provexis (LON:PXS) and Shield Therapeutics (LON:STX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.
Shield Therapeutics received 154 more outperform votes than Provexis when rated by MarketBeat users. Likewise, 75.17% of users gave Shield Therapeutics an outperform vote while only 64.21% of users gave Provexis an outperform vote.
Shield Therapeutics has a net margin of 0.00% compared to Provexis' net margin of -83.03%. Provexis' return on equity of -75.88% beat Shield Therapeutics' return on equity.
Provexis has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Shield Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
In the previous week, Shield Therapeutics had 1 more articles in the media than Provexis. MarketBeat recorded 1 mentions for Shield Therapeutics and 0 mentions for Provexis. Shield Therapeutics' average media sentiment score of 0.67 beat Provexis' score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the news media.
6.4% of Provexis shares are owned by institutional investors. Comparatively, 15.8% of Shield Therapeutics shares are owned by institutional investors. 21.4% of Provexis shares are owned by company insiders. Comparatively, 56.2% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Provexis has higher earnings, but lower revenue than Shield Therapeutics.
Summary
Shield Therapeutics beats Provexis on 8 of the 13 factors compared between the two stocks.
Get Provexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Provexis Competitors List
Related Companies and Tools
